Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard A. Hill on July 14, 1998 and is headquartered in Aliso Viejo, CA.
Sector:
Health Technology
Industry:
Medical Specialties
Employees:
1,094
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Glaukos Corporation market cap is $14.09B.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Glaukos Corporation 52 week high is $255.19 as of November 20, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Glaukos Corporation 52 week low is $93.78 as of November 20, 2026.
Glaukos Corporation stock price today is $237.31.
Glaukos Corporation stock price yesterday was $238.10.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Glaukos Corporation's P/E ratio is -80.86.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Glaukos Corporation P/B ratio is 19.6409.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Glaukos Corporation 50-day moving average is $189.55.